LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive (<i>RET</i>+) NSCLC.Jonathan W. Goldman, Maximilian J. Hochmair, Guoping Li et al.|Journal of Clinical Oncology|2024Cited by 1
LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive (<i>RET</i>+) NSCLC.Theresa Bayt, Maximilian J. Hochmair, Jonathan W. Goldman et al.|Journal of Clinical Oncology|2024Cited by 0